Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) is one of the stocks that will double in 2026. On November 24, JonesTrading analyst Soumit Roy maintained a bullish stance on the company, with a Buy rating.
On the same day, Day One Biopharmaceuticals also announced 3-year follow-up results from the pivotal Phase 2 FIREFLY-1 trial of OJEMDA (tovorafenib). This updated data, derived from the ongoing FIREFLY-1 trial (Arm 1) with a median study duration of 40.6 months (data cutoff June 6 this year), expands on the previously reported clinically meaningful results.
Tovorafenib is a Type II RAF kinase inhibitor approved by the US FDA for treating pediatric patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma/pLGG harboring a BRAF fusion or rearrangement. The approval was granted under accelerated approval based on the response rate and duration of response.
No new safety signals were identified in this updated three-year analysis. Grade 3 or higher adverse events most commonly reported included decreased growth velocity, anemia, increased blood creatine phosphokinase, maculopapular rash, and increased alanine aminotransferase.
Day One Biopharmaceuticals Inc. is a commercial-stage company that advances class medicines for childhood and adult diseases with equal intensity in the US.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
